Global Transmucosal Drug Delivery Devices Market Size, Share, Growth Analysis Report - Forecast 2034

Global Transmucosal Drug Delivery Devices Market: Industry Perspective

The global transmucosal drug delivery devices market size was worth around USD 46.63 Billion in 2024 and is predicted to grow to around USD 86.64 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 6.39% between 2025 and 2034. The report analyzes the global transmucosal drug delivery devices market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the transmucosal drug delivery devices industry.

Request Free Sample

The report analyzes the global Transmucosal Drug Delivery Devices market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the transmucosal drug delivery devices industry.           

Global Transmucosal Drug Delivery Devices Market: Overview

For therapeutic reasons, transdermal drug delivery systems—an alternative to oral intravascular, subcutaneous, and transmucosal routes—transmit drugs through the skin. For businesses involved in its value chain, the transmucosal drug delivery system offers several advantages over traditional drug administration methods. The ability to avoid the body's inherent defense systems is one of the most important advantages of transmucosal medicine delivery. Due to a sizable target market that would need frequent drug delivery devices for diagnosis and treatment, the transmucosal drug delivery devices market is anticipated to expand in years to come.

Global Transmucosal Drug Delivery Devices Market: Growth Drivers

The growing prevalence of chronic diseases such as cancer, cardiovascular, diabetes, and others are expected to propel the global transmucosal drug delivery devices market over the forecast period. For instance, according to the data provided by Cancer Research UK, if incidence remains steady and population growth & aging continue at current rates, there will be 28 million new cancer cases globally each year by 2040.

This is a 54.9% increase over 2020 and is predicted to be larger in males (60.6% increase) than in females (48.8% increase). Similarly, according to the National Institute of Health figure, diabetes is expected to affect 9.3% (463 million people) of the global population in 2019, increasing to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. The frequency is greater in cities (10.8%) than in rural regions (7.2%) and in high-income nations (10.4%) than in low-income countries (4.0%). Thus, the aforementioned facts support the market revenue growth.

Transmucosal Drug Delivery Devices Market: Restraints

Due to strict regulatory norms, the development and licensing procedure for transmucosal medication delivery devices can be complicated and time-consuming. Companies in this transmucosal drug delivery devices industry may encounter difficulties adhering to the requirements of numerous health authorities and guaranteeing safety and efficacy.

In addition, devices for transmucosal drug administration might not be appropriate for all prescription drugs. Some medications may not be suitable for absorption through mucosal membranes or may irritate or harm tissues, which restricts their usage with these delivery methods. Thus, this is expected to act as a major restraint for the market growth over the forecast period.

Transmucosal Drug Delivery Devices Market: Opportunities

The increasing collaboration among the market players to enhance its position in the drug delivery devices industry is expected to offer a lucrative opportunity for market revenue growth over the forecast period. For instance, in December 2022, the conclusion of the merger of the two businesses was announced by Kindeva Drug Delivery and Meridian Medical Technologies. A top worldwide contract development and manufacturing organization ("CDMO") specializing in drug-device combo products have been produced as a result of the combination.

The combined company will do business as Kindeva, with Meridian doing business as "Meridian Medical Technologies, a Kindeva Company". With experience and technology covering the parenteral, inhalation, transdermal, and intradermal modes of administration, the new Kindeva will offer a wider variety of drug delivery capabilities. The merger of Kindeva and Meridian establishes a certain market leader in the CDMO industry for drugs and devices. The expanded scope and selection of medication delivery options will be advantageous to their clients.

Transmucosal Drug Delivery Devices Market: Challenges

Transmucosal drug delivery device development and production can be expensive, especially for small and medium-sized businesses. The transmucosal drug delivery devices market expansion may be hampered by the costs associated with research, development, clinical trials, and production. Moreover, due to their chemical properties, stability issues, or dosage needs, several medication formulations might not be appropriate for transmucosal administration. The variety of medications that can be efficiently given using these devices may be constrained by this limitation.

Key Insights

• As per the analysis shared by our research analyst, the global transmucosal drug delivery devices market is estimated to grow annually at a CAGR of around 6.39% over the forecast period (2025-2034).
• Regarding revenue, the global transmucosal drug delivery devices market size was valued at around USD 46.63 Billion in 2024 and is projected to reach USD 86.64 Billion by 2034.
• The transmucosal drug delivery devices market is projected to grow at a significant rate due to Growing demand for pain-free, fast-acting drug delivery solutions drives adoption. Rise in chronic disease treatments and innovations in formulations support growth.
• Based on Dosage Form, the Buccal segment is expected to lead the global market.
• On the basis of Drug Type, the Pain Management Drugs segment is growing at a high rate and will continue to dominate the global market.
• Based on the End-user, the Hospitals segment is projected to swipe the largest market share.
• By Distribution Channel, the Hospital Pharmacies segment is expected to dominate the global market.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Global Transmucosal Drug Delivery Devices Market: Report Scope

Global Transmucosal Drug Delivery Devices Market: Segmentation Analysis

The global transmucosal drug delivery devices market is segmented based on Dosage Form, Drug Type, End-user, Distribution Channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2025 to 2034.

Based on Dosage Form, the global transmucosal drug delivery devices market is divided into Buccal, Sublingual, Nasal, Rectal, Vaginal.

On the basis of Drug Type, the global transmucosal drug delivery devices market is bifurcated into Pain Management Drugs, Nausea & Vomiting Relief, Smoking Cessation, Others.

By End-user, the global transmucosal drug delivery devices market is split into Hospitals, Clinics, Home Care Settings, Others.

In terms of Distribution Channel, the global transmucosal drug delivery devices market is categorized into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

The Regional, this segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America,and the Middle East and Africa.

Global Transmucosal Drug Delivery Devices Market: Regional Analysis 

The Transmucosal Drug Delivery Devices Market from 2025 to 2034 is expected to witness robust growth across key regions, driven by advancements in drug delivery technology and increasing demand for non-invasive therapeutic options. North America is anticipated to lead the market due to the presence of major pharmaceutical companies, rising healthcare expenditures, and early adoption of innovative drug delivery methods. Europe follows closely, benefiting from a strong regulatory framework supporting patient-centric treatments and a growing geriatric population. Meanwhile, the Asia-Pacific region is projected to experience the fastest growth, fueled by expanding healthcare infrastructure, increasing awareness of alternative drug delivery systems, and rising investments in research and development, particularly in countries like China, India, and Japan. Latin America and the Middle East & Africa are also poised for moderate growth as healthcare access improves and demand for convenient, fast-acting drug administration rises in emerging markets.

Global Transmucosal Drug Delivery Devices Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the transmucosal drug delivery devices market on a global and regional basis.

The global transmucosal drug delivery devices market is dominated by players like:

• Abbott
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Slan Medicinal Holdings LTD
• MMB Healthcare LLC.
• BioDelivery Sciences International Inc.
• Mylan N.V.
• Novartis AG
• Bristol-Myers Squibb Company
• Johnson & Johnson Private Limited
• Antares Pharma
• BD
• 3M
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• Endo International plc
• Echo Pharmaceuticals B.V.
• B. Braun Melsungen AG
• Baxter
• GlaxoSmithKline plc
• Acrux Limited among others.

Global Transmucosal Drug Delivery Devices Market: Segmentation Analysis

The global transmucosal drug delivery devices market is segmented as follows;

By Dosage Form

• Buccal
• Sublingual
• Nasal
• Rectal
• Vaginal

By Drug Type

• Pain Management Drugs
• Nausea & Vomiting Relief
• Smoking Cessation
• Others

By End-user

• Hospitals
• Clinics
• Home Care Settings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Transmucosal Drug Delivery Devices Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America